Verastem (VSTM) Stock Forecast & Price Target

Verastem is supported by a compelling mix of approved-product traction and pipeline optionality, with AVMAPKI FAKZYNJA launched in 2025 for LGSOC and potential to address an unmet-need niche of about 1K-2K new patients per year. Its lead KRAS G12D asset VS-7375 has shown competitive efficacy across PDAC, CRC, and NSCLC, including a 41% ORR in 2L PDAC, a 33% ORR in CRC, and a favorable safety profile that appears to preserve combination flexibility versus peers with higher grade ≥3 toxicity. Fundamentally, the company’s outlook is strengthened by a biologically rational RAF/MEK and FAK strategy, regulatory alignment for 1L phase III development, and meaningful revenue upside from a portfolio that could exceed $1.2B to $1.3B in combined opportunity if execution remains strong.

Verastem is viewed negatively because its lead launch, Avmapki Fakzynja, still lacks sizable and definitive randomized data, making durability of efficacy and commercial adoption difficult to underwrite. Competitive pressure, especially against agents with cleaner tolerability, could limit enrollment and market uptake, while the company’s own data show liver-enzyme and GI safety signals that may force a trade-off between efficacy and safety. Beyond the launch asset, most expansion opportunities remain early stage and without proof of concept, so if RAMP-301 disappoints or safety concerns persist, the equity could revert toward net cash value with minimal pipeline support.